$28.96
2.36% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
US28036F1057
Symbol
EWTX
Sector
Industry

Edgewise Therapeutics Inc Stock price

$28.74
-3.46 10.75% 1M
+11.24 64.23% 6M
+17.80 162.71% YTD
+16.64 137.52% 1Y
+14.33 99.44% 3Y
-1.26 4.20% 5Y
-1.26 4.20% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.92 3.10%
ISIN
US28036F1057
Symbol
EWTX
Sector
Industry

Key metrics

Market capitalization $2.72b
Enterprise Value $2.23b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 5.55
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-147.15m
Free Cash Flow (TTM) Free Cash Flow $-110.10m
Cash position $492.54m
EPS (TTM) EPS $-1.49
P/E forward negative
Short interest 8.87%
Show more

Is Edgewise Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Edgewise Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Edgewise Therapeutics Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Edgewise Therapeutics Inc forecast:

Buy
100%

Financial data from Edgewise Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.16 2.16
77% 77%
-
-2.16 -2.16
77% 77%
-
- Selling and Administrative Expenses 27 27
24% 24%
-
- Research and Development Expense 116 116
48% 48%
-
-145 -145
43% 43%
-
- Depreciation and Amortization 2.16 2.16
77% 77%
-
EBIT (Operating Income) EBIT -147 -147
43% 43%
-
Net Profit -124 -124
39% 39%
-

In millions USD.

Don't miss a Thing! We will send you all news about Edgewise Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edgewise Therapeutics Inc Stock News

Neutral
Business Wire
13 days ago
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals with Becker muscular dystrophy. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to protect muscle against contraction-induc...
Neutral
Business Wire
23 days ago
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the company's relationship with Dr. Han Phan at Rare Disease Research. On November 27, 2024, the U.S. Food and Drug Administration (FDA) issued a warning letter to Dr. Phan based on a 2024 site inspection related to her work with ...
Neutral
Business Wire
about one month ago
BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 1 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and wi...
More Edgewise Therapeutics Inc News

Company Profile

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Head office United States
CEO Kevin Koch
Employees 88
Founded 2017
Website www.edgewisetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today